Date: January 19, 2018
Administrative Circular: 2018:02

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2: Immunization, Part 2-Immunization of Special Populations, Part 4-
Biological Products & Part 5-Adverse Events Following Immunization

Part 2-Immunization of Special Populations

Chronic Kidney Disease
- The BC Renal Agency Hepatitis B Guidelines document date has been updated to November 2017.

Please remove page numbers: 1-3 dated October 2017
Please add new page numbers: 1-3 dated January 2018

Individuals with Neurological Conditions
- Pneumococcal vaccine has been added to the table of “Recommended vaccines for individuals with pre-existing neurological conditions”, as pneumococcal polysaccharide and/or conjugate vaccine (depending on age) are recommended for those with chronic neurological conditions that may impair clearance of oral secretions.
- Content related to Guillain-Barré syndrome (GBS) and Menactra® has been removed as GBS is no longer a contraindication for receipt of Menactra®.

Please remove page numbers: 1-2 dated January 2009
Please add new page numbers: 1-2 dated January 2018
Health Care Workers

- Content regarding acceptable proof of immunity to hepatitis B has been added for clarity, indicating that laboratory testing for anti-HBs in the absence of a documented complete vaccine series is not acceptable. A hyperlink has been added to Part 1-Immunization Schedules, 1.1 Consideration of Immunization History for more information regarding adequate proof of vaccination history.

Part 4-Biological Products

Tetanus-Diphtheria-Acellular Pertussis (ADACEL® and BOOSTRIX®)

- INDICATIONS has been updated to include “booster dose for individuals 4 years of age and older who are up-to-date for polio immunization”. Associated footnote D has been added, indicating that Tdap is not indicated for primary immunization of children less than 7 years of age.

Hepatitis B Vaccine (ENGERIX®-B)

- Content under the BOOSTER DOSES and SEROLOGICAL TESTING subsections has been revised to include the updated subsection titles and hyperlink to the updated Communicable Disease Control Manual, Chapter 1: Hepatitis B guidelines.

Hepatitis B Vaccine (RECOMBIVAX HB®)

- Content under the BOOSTER DOSES and SEROLOGICAL TESTING subsections has been revised to include the updated subsection titles and hyperlink to the updated Communicable Disease Control Manual, Chapter 1: Hepatitis B guidelines.
- SPECIAL CONSIDERATIONS has been updated to remove the content related to a 0.5 mL (5mcg) dose representing the “Hepatitis B Vaccine Higher Dose” for children less than 11 years of age, as this is now the standard dose for this age cohort.
Hepatitis B Higher Dose Schedule

- Footnote C has been revised to indicate that the RECOMBIVAX HB® Dialysis Formulation (40 mcg/1 mL) may be used for kidney transplant candidates and recipients.

Please remove page number: 1 dated October 2017
Please add new page number: 1 dated January 2018

Hepatitis B Vaccine Program for Chronic Kidney Disease Clients

- The BC Renal Agency Hepatitis B Guidelines document date has been updated to November 2017.

Please remove page number: 1 dated October 2017
Please add new page number: 1 dated January 2018

Measles, Mumps, Rubella (MMR II® and PRIORIX®)

- The following indication has been revised for clarity: “Infants from 6-11 months of age who are traveling to measles endemic areas or who are identified as contacts of a measles case”.

Please remove page numbers: 1-4 dated January 2016
Please add new page numbers: 1-4 dated January 2018

Tetanus Immune Globulin (Tlg) HyperTET®S/D

- DOSES AND SCHEDULE has been revised to remove content regarding the consideration of a 2nd dose of Tig 30 days after the 1st dose. A 2nd dose is not recommended as the half-life of Tlg is 23 days, and extends beyond the 21 day incubation period for tetanus.

Please remove page numbers: 1-2 dated September 2015
Please add new page numbers: 1-2 dated January 2018

Part 5-Adverse Events Following Immunization

- The temporal criteria for “intussusception or hematochezia” following receipt of rotavirus vaccine has been corrected from “0-42 hours” to 0-42 days”.

Please remove page number: 10 dated November 2016
Please add new page number: 10 dated January 2018
If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

[Signature]

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:
BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer

Dr. Bonnie Henry
Deputy Provincial Health Officer

Dr. Mark Tyndall
Executive Medical Director
BC Centre for Disease Control, and
Deputy Provincial Health Officer

Craig Thompson
Director, Provincial Immunization Services

Brian Sagar
Acting Executive Director, Public Health Services & Office of Aboriginal Health